Tagged with IP

Pharma The Vice-Chairman of the Public Health Enhancement Fund talks about how the shortage of medical doctors and the fight against TB, HIV and AIDS in South Africa led the health Minister and the private health sector to create a public health enhancement fund and how the private sector is pulling resources…

pharma The managing director of Adcock Ingram’s prescription business, Ashley Pearce highlights the division’s strategic placement within the group’s overall activities, and how he plans on leveraging partnerships with various multinationals, expand into biosimilars and grow the generics business into a market leading position. Adcock Ingram has undergone several strategic changes…

pharma The CEO and founder of ModiQuest discusses how, with its unique, fully-integrated antibody generation and development platform, the company is developing antibodies for potentially groundbreaking therapies for the prevention and treatment of rheumatoid arthritis and growing its already well-established CRO arm serving clients from around the world. Could you introduce…

pharma CEO of Pantarhei since its inception in 2001, Herjan Coelingh Bennink outlines the company’s vision to develop new applications for existing compounds in the fields of women’s health and oncology with therapies with real medical advantages including a contraceptive pill which does not increase the risk of thrombosis and improved…

pharma Hans Schikan offers insights into the flourishing Dutch life sciences sector and the attractiveness of the local eco-system, citing a combination of the right science and the right attitude of people as the key formula for success. In 2014/2015, three Dutch biotechs (UniQure, ProQR, Galapagos) went public on Nasdaq, and…

Algeria PharmaBoardroom recently conducted a roundtable event with the key opinion leaders of Algeria’s healthcare sector. This is a sample of the conversation at our recent roundtable. Algeria’s youthful pharmaceutical landscape includes an array of state-controlled entities of an industrial or commercial nature alongside more conventional regulatory apparatus.  THE NATIONAL AGENCY FOR…

Pharma The CEO of IPASA reveals how over the last ten months the priority has been to reach out to different stakeholders, rebuilding trust with the department of health, with patients and physicians; why a National Health Insurance scheme should be established to act as a true merger between the public and private…

Pharma Tugce Gozacan (pictured) and Okan Gozacan, Owner and Chairman of Marmara Ecza respectively, discuss what qualities are crucial for suppliers in the pharmaceutical industry, their process for forming partnerships and attracting clients, and their vision for a future with Iran as a major player. As an introduction for our readers,…

pharma Ileana Quiñones, president and general manager of iPR-AstraZeneca, discusses the clear strategy of the affiliate in being a leading manufacturer in Puerto Rico and the steps necessary to ensure their place in the country and within the AstraZeneca organization. Where is AstraZeneca focused today and how does the Puerto Rican…

Philips PharmaBoardroom briefly met up with Henk de Jong, CEO of Philips Latin America at the Financial Times LatAm Healthcare & Life Sciences Summit in Miami in September 2015. He discusses the importance of the Philips brand for both its consumer and healthcare divisions. You have a long history working in…

Pharma Peter Fuller provides us with an update on the integration of Covidien businesses, and explains how Medtronic is bringing innovation to South African patients and contributing to the improvement of the South African healthcare. Fuller is Vice President & General Manager of Medtronic South Africa, SADC & EAC.  In January 2015, Covidien was bought…

Research Arnaud Lagesse, CEO of GML, the largest company in Mauritius and the third largest company in the Indian Ocean, discusses his company’s successful diversification into the life sciences sector, with the creation of GML Life. The history of GML has always been linked to the development of the Mauritian economy.…